MicroRNA-320a acts as a tumor suppressor by targeting BCR/ABL oncogene in chronic myeloid leukemia

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Xishan, Zhu ^a   Ziying, Lin ^a   Jing, Du ^b   Gang, Liu ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b Clinical Laboratory   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; MICRORNA; MIRN320 MICRORNA, HUMAN;

ADOLESCENT; ADULT; AGED; ANIMAL; APOPTOSIS; C57BL MOUSE; CANCER STEM CELL; CELL MOTION; CHRONIC MYELOID LEUKEMIA; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; K-562 CELL LINE; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGY; TUMOR SUPPRESSOR GENE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANIMALS; APOPTOSIS; CELL MOVEMENT; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, TUMOR SUPPRESSOR; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MICE, INBRED C57BL; MICRORNAS; MIDDLE AGED; NEOPLASTIC STEM CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 84938651885     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12460     Document Type: Article

References (36)

1. Cai, J., et al. Transferred BCR/ABL DNA from K562 extracellular vesicles causes chronic myeloid leukemia in immunodeficient mice. PLoS One. 9, 334-341 (2014).
2. Joshi, D., Chandrakala, S., Korgaonkar, S., Ghosh, K. & Vundinti, B. R. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients. Gene. 542, 109-112 (2014).
3. Nishioka, C., et al. Downregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors. Cancer Sci. 105, 297-307 (2014).
4. Xishan, Z., Xinna, Z., Baoxin, H. & Jun, R. Impaired immunomodulatory function of chronic myeloid leukemia cancer stem cells and the possible mechanism involved in it. Cancer Immunol Immunother. 62, 689-703 (2013).
5. Shibuta, T., et al. Imatinib induces demethylation of miR-203 gene: an epigenetic mechanism of anti-tumor effect of imatinib. Leuk Res. 37, 1278-1286 (2013).
6. Shahrabi, S., et al. New insights in cellular and molecular aspects of BM niche in chronic myelogenous leukemia. Tumour Biol. 35, 10627-10633 (2014).
7. Takahashi, R. U., Miyazaki, H. & Ochiya, T. The Roles of MicroRNAs in Breast Cancer. Cancers (Basel). 7, 598-616 (2015).
8. Xu, Y. M., et al. Regulation of miRNAs Affects Radiobiological Response of Lung Cancer Stem Cells. Biomed Res Int. 32, 123-129 (2015).
9. Nicolaidou, V. & Koufaris, C. MicroRNA responses to environmental liver carcinogens: Biological and clinical significance. Clin Chim Acta. 445, 25-33 (2015).
10. Shrestha, S., et al. A systematic review of microRNA expression profiling studies in human gastric cancer. Cancer Med. 3, 878-88 (2014).
11. Rodríguez-Montes, J. A. & Menéndez Sánchez, P. Role of micro-RNA in colorectal cancer screening. Cir Esp. 92, 654-658 (2014).
12. Swartling, F. J., Čančer, M., Frantz, A., Weishaupt, H. & Persson, A. I. Deregulated proliferation and differentiation in brain tumors. Cell Tissue Res. 359, 225-254 (2015).
13. Bottoni, A. & Calin, G. A. MicroRNAs as main players in the pathogenesis of chronic lymphocytic leukemia. Microrna. 2, 158-164 (2014).
14. Zhu, Y. & Qian, S. X. Clinical efficacy and safety of imatinib in the management of Ph(+ ) chronic myeloid or acute lymphoblastic leukemia in Chinese patients. Onco Targets Ther. 7, 395-404 (2014).
15. Cai, J., et al. Transferred BCR/ABL DNA from K562 extracellular vesicles causes chronic myeloid leukemia in immunodeficient mice. PLoS One. 9, e105200 (2014).
16. Rondanin, R., et al. Inhibition of activated STAT5 in Bcr/Abl expressing leukemia cells with new pimozide derivatives. Bioorg Med Chem Lett. 24, 4568-4574 (2014).
17. Li, Y., et al. Inhibition of BCR/ABL protein expression by miR-203 sensitizes for imatinib mesylate. PLoS One. 8, 276-284 (2013).
18. Li, Y., et al. miR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR/ABL1 protein. Exp Cell Res. 319, 1094-1101 (2013).
19. Verma, M., et al. Mathematical modelling of miRNA mediated BCR.ABL protein regulation in chronic myeloid leukaemia vis-avis therapeutic strategies. Integr Biol (Camb). 5, 543-554 (2013).
20. Xishan, Z., Xu, Z., Lawei, Y. & Gang, L. Hemangioblastic characteristics of cancer stem cells in chronic myeloid leukemia. Clin Lab. 58, 607-13 (2012).
21. Liu, Y., Song, Y., Ma, W., Zheng, W. & Yin, H. Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR/ABL1 expression in chronic myeloid leukemia. Leuk Res. 37, 349-56 (2013).
22. Xu, C., et al. BCR/ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia. Oncogene. 33, 44-54 (2014).
23. Burchert A. Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistence. Curr Hematol Malig Rep. 9, 9-16 (2014).
24. Lopotová, T., Záčková, M., Klamová, H. & Moravcová, J. MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR/ABL regulatory loop? Leuk Res. 35, 974-977 (2011).
25. Li, Y., et al. Methylation and decreased expression of SHP-1 are related to disease progression in chronic myelogenous leukemia. Oncol Rep. 31, 2438-2446 (2014).
26. Brechbiel, J., Miller-Moslin, K. & Adjei, A. A. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer. Cancer Treat Rev. 40, 750-759 (2014).
27. Ringel, F., et al. Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines. Acta Haematol. 132, 75-86 (2014).
28. Xu, D., et al. Thymoquinone induces G2/M arrest, inactivates PI3K/Akt and nuclear factor-κ B pathways in human cholangiocarcinomas both in vitro and in vivo. Oncol Rep. 31, 2063-2070 (2014).
29. Kamo, N., Ke, B., Busuttil, R. W. & Kupiec-Weglinski, J. W. PTEN-mediated Akt/β -catenin/Foxo1 signaling regulates innate immune responses in mouse liver ischemia/reperfusion injury. Hepatology. 57, 289-298 (2013).
30. Li, J., Liang, X. & Yang, X. Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-κ B pathways. Oncol Rep. 28, 501-510 (2012).
31. Kovacic, B., Rosner, M., Schipany, K., Ionce, L. & Hengstschläger, M. Clinical impact of studying epithelial-mesenchymal plasticity in pluripotent stem cells. Eur J Clin Invest. 45, 415-422 (2015).
32. Vella, L. J. The emerging role of exosomes in epithelial-mesenchymal-transition in cancer. Front Oncol. 19, 361-376 (2014).
33. Puissant, A. l., et al. Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness. J Mol Cell Biol. 4, 207-220 (2012).
34. Bai, J. X., et al. Tamoxifen represses miR-200 microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating c-Myc in endometrial carcinoma cell lines. Endocrinology. 154, 635-645 (2013).
35. Gwak, J. M., et al. MiRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cellphenotype, and tumor progression in breast cancer. Breast Cancer Res Treat. 147, 39-49 (2014).
36. Zhang, Z. l., Liu, S., Shi, R. & Zhao, G. miR-27 promotes human gastric cancer cell metastasis by inducing epithelial-tomesenchymal transition. Cancer Genet. 204, 486-491 (2011).